Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Tuberous Sclerosis Complex-associated Refractory Seizures 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Has results × Anticonvulsants × Clear all
NCT01713946 2018-11-07

EXIST-3

Novartis

Phase 3 Completed
366 enrolled 38 charts 1 FDA

Tuberous Sclerosis Complex-associated Refractory Seizures

NCT00045708 2017-10-18

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas

National Cancer Institute (NCI)

Phase 1/2 Completed
57 enrolled 18 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡